Uptake of inhaled generics will be influenced by device type.
By Jacoba Procter, Content Manager
16 March 2016
I joined Datamonitor Healthcare as an analyst at the end of 2009 and I worked for a number of years covering immunology ...
Read full bio
Uptake of inhaled generics is expected to differ considerably from, for example, oral generics, with device type playing a key role.
Datamonitor Healthcare surveyed 229 pulmonologists and primary care physicians across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain an understanding of current and future prescribing patterns for asthma. The survey included a question aimed at gaining a better understanding of future generic use in asthma treatment and the influence that inhaler type has on prescribing practices. Respondents were asked what percentage of their asthma patients currently treated with a branded inhaled therapy they would expect to switch from the brand to a generic version, if it became available, based on the generic’s device type.
As shown in the table below, Datamonitor Healthcare’s survey highlighted that device type will play a key role in switching to generics. While switching to generics is expected to be greater if the generic is available in the same inhaler type as the reference product, across both scenarios the results also show a hesitation to use inhaled generics in asthma treatment, highlighting a key difference compared to other markets.
Datamonitor Healthcare’s Asthma: Treatment explores the impact of generic entry in the asthma market, as well as a detailed look at current treatment algorithms and prescribing influences.
Register for a free demo to find out more information on our asthma treatment report >>>
If you are a current subscriber you can view the Asthma treatment report here